CHRU Besancon
Besançon, 25030, France
NCT Number: NCT02861430
Unmask Trial aims to evaluate the Kappa concordance between immunochemistry and molecular biology to detecting cancer cells in sentinel lymph node in patients undergoing colectomy for non metastatic colon cancer.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Besançon, 25030, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 month
The primary outcome is the rate of concordance between the number of positive sentinel lymph nodes detected by immunochemistry using an anti-cytokeratin antibody (KL1) and molecular biology targeting CK20 on tumoral RNA after RT-PCR.
The rate of positivity of the sentinel lymph nodes will be then compared to the standard technique using HES coloration used in routine pathological examination.
Only the result using the routine examination will be used to decide whether the patient should benefit from an adjuvant chemotherapy.
Time frame: 3 years
Centre Hospitalier Universitaire de Besancon
Other
Acronym: UNMASK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00469339
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsNCT06714292
Colon Cancer, Colonic Diseases
Goyang-si, Gyeonggi-do, South Korea
View Trial DetailsNCT07736131
Colon Cancer, Colonic Diseases
View Trial DetailsNCT05513742
Colon Cancer, Colonic Diseases
Hot Springs, Arkansas, United States
View Trial Details